Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drais Pharmaceuticals, a drug development company, and Diatos, a biopharmaceutical company, have entered into a global agreement to develop and commercialize DTS-108 for the treatment of solid tumors. DTS-108 is currently ready to begin Phase I clinical trials in Europe for the treatment of patients with advanced or metastatic solid tumors.
Subscribe to our email newsletter
Under the terms of the agreement, the license grants exclusive rights to Drais to develop and commercialize DTS-108 worldwide. In return, Diatos is expected to receive an upfront payment, development milestones and sales milestones, plus royalties. The total value of the non-royalty portion of the partnership is valued at $46.9m.
Donna Tempel, president and CEO of Drais Pharmaceuticals, said: DTS-108 will become a key asset for Drais and we believe strongly in its potential to provide significant benefits over existing cancer therapies. This is a major step for Drais as we continue to build our therapeutic pipeline.
John Tchelingerian, president and CEO of Diatos, said: We are confident that DTS-108 will fulfill its potential as a valuable addition to the physician’s armamentarium in the treatment of cancer. This transaction also represents further validation of the Diatos Vectocell technology platform.